The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

The report also indicates that while PAMA has cut spending on routine tests, overall lab spending has risen as genetic testing continues to grow.

The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and ...